Biotest AG (Biotest AG) EV-to-Revenue : 2.27 (As of Jun. 08, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Biotest AG EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Biotest AG's enterprise value is $1,989.6 Mil. Biotest AG's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $875.9 Mil. Therefore, Biotest AG's EV-to-Revenue for today is 2.27.

The historical rank and industry rank for Biotest AG's EV-to-Revenue or its related term are showing as below:

BIESF' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.77 Med: 2.29 Max: 4.44
Current: 2.29

During the past 13 years, the highest EV-to-Revenue of Biotest AG was 4.44. The lowest was 0.77. And the median was 2.29.

BIESF's EV-to-Revenue is ranked better than
77.63% of 1037 companies
in the Biotechnology industry
Industry Median: 7.86 vs BIESF: 2.29

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-08), Biotest AG's stock price is $30.48. Biotest AG's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $22.01. Therefore, Biotest AG's PS Ratio for today is 1.39.

Biotest AG EV-to-Revenue Historical Data

The historical data trend for Biotest AG's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG EV-to-Revenue Chart

Biotest AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

2.59

3.13

4.01

4.13

3.19

Biotest AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															3.08	2.99	2.36	3.19	1.95

Competitive Comparison of Biotest AG's EV-to-Revenue

For the Biotechnology subindustry, Biotest AG's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotest AG's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biotest AG's EV-to-Revenue falls into.

Biotest AG EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Biotest AG's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	1989.616	/	875.872
	=	2.27

Biotest AG's current Enterprise Value is $1,989.6 Mil.
Biotest AG's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $875.9 Mil.

Biotest AG (OTCPK:BIESF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Biotest AG's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	30.48	/	22.006
	=	1.39

Biotest AG's share price for today is $30.48.
Biotest AG's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.01.

Biotest AG EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biotest AG's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotest AG (Biotest AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (OTCPK:BIESF) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

BIO3:Germany BIO3:Austria

Address

Landsteinerstrasse 5, Dreieich, DEU, 63303

Website

https://www.biotest.com

Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.